Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-31
2007-07-31
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S341500, C548S335100
Reexamination Certificate
active
11018049
ABSTRACT:
Certain imidazole compounds are CCK1 modulators useful in the treatment of CCK1 mediated diseases.
REFERENCES:
patent: 4826868 (1989-05-01), Wachter et al.
patent: 5011851 (1991-04-01), Meanwell
patent: 5051518 (1991-09-01), Murray et al.
patent: 5164381 (1992-11-01), Wachter et al.
patent: 5717100 (1998-02-01), Selnick et al.
patent: 5965583 (1999-10-01), Beers et al.
patent: 6083949 (2000-07-01), Liverton et al.
patent: 0442448 (1991-08-01), None
patent: 0293220 (1994-08-01), None
patent: WO 9205148 (1992-04-01), None
patent: WO 9711704 (1997-04-01), None
patent: WO 9712876 (1997-04-01), None
patent: WO 9901449 (1999-01-01), None
patent: WO 0138324 (2001-05-01), None
patent: WO 0166539 (2001-09-01), None
patent: WO 01/85723 (2001-11-01), None
patent: WO 0185724 (2001-11-01), None
patent: WO 0190078 (2001-11-01), None
patent: WO 04/07463 (2004-01-01), None
Peter et al. Digestive Disease 2006, 24, 70-82.
Crawley, J.N. ESI Special Topics, Oct. 2001; http://www.esi-topics.com/schizophrenia/interviews/dr-jacqueline-n-crawley.html.
de Tullio, P. et al. Therapeutic and Chemical Developments of Cholecystokinin Receptor Ligands.Exp. Opin. Invest. Drugs2000, 9(1), 129-146.
Gigoux, V. et al. Arginine 336 and Asparagine 333 of the Human Cholecystokinin-A Receptor Binding Site Interact with the Penultimate Aspartic Acid and the C-Terminal Amide of Cholecystokinin.J. Biol. Chem.1999, 274(29), 20457-20464.
Harper, E.A. et al. Analysis of Variation in L-365,260 Competition Curves in Radioligand Binding Assays.Br. J. Pharmacol.1996, 118, 1717-1726.
Hull, R.A. et al. 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)—A Selective Cholecystokinin CCKA-Receptor Antagonist.Br. J. Pharmacol.1993, 108, 734-740.
Klapars, A. et al. A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-Arylation of Nitrogen Heterocycles.J. Am. Chem. Soc.2001, 123(31), 7727-7729.
Klausner, Y.S. and M. Bodzansky. The Azide Method in Peptide Synthesis: Its Scope and Limitations.Synthesis1974, 8, 549-559.
Morton, M.F. et al. Pharmacological Comparison of the Alternatively Spliced Short and Long CCK2 Receptors.Br. J. Pharmacol.2003, 140(1), 218-224.
Saito, T. et al. Total Synthesis of the Furaquinocins.J. Am. Chem. Soc.1998, 120(45), 11633-11644.
Wang, Z. A New Synthesis for Methyl 2-Benzyloxyphenylacetate.Synth. Commun.1999, 29(13), 2361-2364.
Wolfe, J.P. et al. Simple Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates.J. Org. Chem.2000, 65(4), 1158-1174.
Laufer, S.A. et al. Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position.J. Med. Chem.2002, 45, 4695-4705.
Meanwell, N.A. et al. Nonprostanoid Prostacyclin Mimetics. 3. Structural Variations of the Diphenyl Heterocycle Moiety.J. Med. Chem.1992, 35, 3498-3512.
International Search Report dated May 23, 2005, for corresponding international application PCT/US2004/043191.
Breitenbucher J. Guy
Hack Michael D.
Sehon Clark A.
Harbour John
Janssen Pharmaceutica N.V.
Nolan Jason M.
Saeed Kamal A.
LandOfFree
CCK-1 receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCK-1 receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCK-1 receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796337